Shanghai Kaibao Pharmaceutical CO.,Ltd

300039

CNE100000JZ3

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
6.16 ^CNY	+0.82%		+2.16%	-7.37%

Apr. 26	Shanghai Kaibao Pharmaceutical Co.,Ltd Proposes Final Dividend for the Year 2023	CI
Apr. 25	Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Shanghai Kaibao Equity Investment Management Co., Ltd. announced that it has received CNY 60 million in funding from Shanghai Kaibao Pharmaceutical CO.,Ltd

December 10, 2020

On December 11, 2021, Shanghai Kaibao Equity Investment Management Co., Ltd. closed the transaction. The company has completed industrial and commercial registration procedures.

Latest news about Shanghai Kaibao Pharmaceutical CO.,Ltd

Shanghai Kaibao Pharmaceutical Co.,Ltd Proposes Final Dividend for the Year 2023	Apr. 26	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Maling Aquarius' President Resigns	Mar. 05	MT
Shanghai Kaibao Pharmaceutical CO.,Ltd Announces Executive Changes	Dec. 25	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-17	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-08	CI
Shanghai Kaibao Pharmaceutical Co.,Ltd. Approves Cash Dividend for 2022, Payable on 26 May 2023	23-05-15	CI
Shanghai Maling Aquarius Names Chairman	23-05-11	MT
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Shanghai Kaibao Pharmaceutical Co.,Ltd Announces the Profit Distribution Proposal for 2022	23-04-19	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-18	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd(XSEC:300039) added to S&P Global BMI Index	22-09-19	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-15	CI
Shanghai Kaibao Pharmaceutical Co.,Ltd Announces Final Cash Dividend on A Shares for 2021, Payable on 16 June 2022	22-06-08	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Approves Cash Dividend for the Year 2021	22-05-20	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Proposes Cash Dividend for 2021	22-04-26	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-25	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Shanghai Kaibao Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-25	CI
Shanghai Kaibao Pharmaceutical Co.,Ltd Announces 2020 Final Profit Distribution Plan, Payable 09 June 2021	21-06-03	CI
Shanghai Kaibao Pharmaceutical Co.,Ltd Approves Cash Dividend	21-05-31	CI
Shanghai Kaibao Pharmaceutical Co.,Ltd Announces Final Dividend Profit Distribution Proposal for 2020	21-04-23	CI

Chart Shanghai Kaibao Pharmaceutical CO.,Ltd

Duration

Period

Chart Shanghai Kaibao Pharmaceutical CO.,Ltd

More charts

Shanghai Kaibao Pharmaceutical CO.,Ltd. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent drugs. The Company's main product is Tanreqing injection, which is used for treatment of upper respiratory tract infections, such as cold and pneumonia. The Company's products include injections, tablets, capsules, granules, vinum and pills, among others. The Company distributes its products in domestic markets.

Sector

Pharmaceuticals

Calendar

2024-06-05 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANGHAI KAIBAO PHARMACEUTICAL CO.,LTD	-7.37%	890M
ELI LILLY AND COMPANY	+26.08%	662B
NOVO NORDISK A/S	+21.85%	546B
JOHNSON & JOHNSON	-4.77%	359B
MERCK & CO., INC.	+16.97%	323B
ABBVIE INC.	+5.69%	290B
ASTRAZENECA PLC	+13.68%	234B
NOVARTIS AG	+3.65%	198B
ROCHE HOLDING AG	-11.12%	194B
PFIZER, INC.	-3.40%	157B

Other Pharmaceuticals

Shanghai Kaibao Pharmaceutical CO.,Ltd

Equities

300039

CNE100000JZ3

Pharmaceuticals

Shanghai Kaibao Equity Investment Management Co., Ltd. announced that it has received CNY 60 million in funding from Shanghai Kaibao Pharmaceutical CO.,Ltd

Latest news about Shanghai Kaibao Pharmaceutical CO.,Ltd

Chart Shanghai Kaibao Pharmaceutical CO.,Ltd

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals